MASIMO CORP

Member Only Articles

AI Health Factor Performance Trends

Latest Insights

15 February, 2025
Masimo Earns 'Strong Buy' Rating with Projected 11.8% Growth for 2025 and 51.4% Stock Surge Over the Past Year
Read More >>
14 February, 2025
Masimo Earns 'Strong Buy' Rating with Projected 11.8% Growth for 2025 and 51.4% Stock Surge Over the Past Year
Masimo (MASI) continues to capture investor attention, holding a prestigious Zacks Rank of #1, signifying a "Strong Buy." The company is anticipated to achieve an impressive growth rate of 11.8% for 2...
Read More
10 February, 2025
Masimo Expected to Outperform Earnings Estimates with 14.4% EPS Growth in Upcoming Q4 2024 Results
Masimo (MASI) is gearing up to release its fourth-quarter fiscal 2024 results on February 25, showcasing a Zacks Rank of #1 (Strong Buy) and an impressive Earnings Surprise Prediction (ESP) of +4.05%....
Read More
09 February, 2025
Masimo Expected to Outperform Earnings Estimates with 14.4% EPS Growth in Upcoming Q4 2024 Results
Masimo (MASI) is gearing up to release its fourth-quarter fiscal 2024 results on February 25, showcasing a Zacks Rank of #1 (Strong Buy) and an impressive Earnings Surprise Prediction (ESP) of +4.05%....
Read More
08 February, 2025
Masimo Projects 11.8% Growth for 2025, Outperforms Industry with 51.4% Share Increase
Masimo (MASI) is generating considerable interest among investors, holding a Zacks Rank of #1 (Strong Buy). The company is projected to achieve an impressive growth rate of 11.8% for 2025, significant...
Read More

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.